Celularity Inc (CELU) stock
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.57−0.05 (-7.75%)
Close on Nov 17, 2026Market cap $18.53MP/E –Yield –
Celularity revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Celularity's revenue for the twelve months ending Jun 30, 2026 was $18.67M, down 58.1% year over year. For fiscal 2025 it was $26.55M, down 51.0% from the year before. The highest annual figure on record is $54.22M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.55M | -51.0% |
| FY2024 | Dec 31, 2024 | $54.22M | +138.1% |
| FY2023 | Dec 31, 2023 | $22.77M | +26.7% |
| FY2022 | Dec 31, 2022 | $17.98M | -15.7% |
| FY2021 | Dec 31, 2021 | $21.34M | +49.4% |
| FY2020 | Dec 31, 2020 | $14.28M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.43M | -5.3% |
| Q1 FY2026 | Mar 31, 2026 | $3.85M | -66.3% |
| Q4 FY2025 | Dec 31, 2025 | $4.10M | -77.4% |
| Q3 FY2025 | Sep 30, 2025 | $5.28M | -43.2% |
| Q2 FY2025 | Jun 30, 2025 | $5.74M | -52.6% |
| Q1 FY2025 | Mar 31, 2025 | $11.43M | -22.2% |
| Q4 FY2024 | Dec 31, 2024 | $18.13M | +49.7% |
| Q3 FY2024 | Sep 30, 2024 | $9.30M | +145.5% |
| Q2 FY2024 | Jun 30, 2024 | $12.11M | +312.2% |
| Q1 FY2024 | Mar 31, 2024 | $14.68M | +273.1% |
| Q4 FY2023 | Dec 31, 2023 | $12.11M | +193.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.79M | -8.4% |
| Q2 FY2023 | Jun 30, 2023 | $2.94M | -22.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.94M | -33.7% |
| Q4 FY2022 | Dec 31, 2022 | $4.13M | -15.0% |
| Q3 FY2022 | Sep 30, 2022 | $4.14M | -61.1% |
| Q2 FY2022 | Jun 30, 2022 | $3.78M | +18.1% |
| Q1 FY2022 | Mar 31, 2022 | $5.94M | +123.1% |
| Q4 FY2021 | Dec 31, 2021 | $4.86M | +49.7% |
| Q3 FY2021 | Sep 30, 2021 | $10.62M | +216.6% |
| Q2 FY2021 | Jun 30, 2021 | $3.20M | – |
| Q1 FY2021 | Mar 31, 2021 | $2.66M | – |
| Q4 FY2020 | Dec 31, 2020 | $3.24M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.36M | – |
See a number that looks wrong?